The agreement provides a framework for supply chain management, packing and shipping, via air or ocean, ground transportation, warehouse storage and distribution to facilities.
COVAXX, the U.S. company developing a multitope synthetic peptide-based vaccine to fight Covid-19, has announced a global logistics partnership with one of the world’s largest shipping and integrated logistics providers Maersk for all transportation and supply chain services that will be needed to deliver COVAXX’s vaccine candidate UB-612 around the world.
Financial terms of the agreement are not disclosed.
“The mission of COVAXX is to defeat Covid-19 and ultimately democratize health worldwide. Maersk will help fulfil this mission by overseeing all logistics activities to ensure efficient transportation to developing countries,” said the release.
End to end vaccine logistics
The agreement provides for end-to-end supply chain management, packing and shipping, via air or ocean, ground transportation, warehouse storage and distribution to facilities to support COVAXX’s requirements for a pharmaceutical grade, temperature-controlled supply chain. COVAXX is planning to manufacture 100 million doses of UB-612 during early 2021, and a billion doses by the end of 2021. The design of the vaccine components will allow for the use of existing cold-chain storage and distribution channels, as the COVAXX vaccine does not require additional infrastructure such as -80⁰C freezers or liquid nitrogen tanks to store materials at extreme temperatures.
Rob Townley, head of special project logistics at Maersk, said, “Efficient and safe delivery of Covid-19 vaccines around the world is the most urgent logistics challenge we face today. A. P. Moller – Maersk is committed to working closely with COVAXX to ensure smooth end-to-end global delivery of this vaccine as soon as it becomes available. Our specialized logistics expertise and the global infrastructure of Maersk make this a perfect match.”
COVAXX’s Covid vaccine COVAXX is developing UB-612 using a high precision, synthetic peptide platform to activate both B-cell and T-cell arms. The investigational vaccine is designed to mimic natural biology and preclinical studies have shown high immunogenicity and levels of neutralizing titers against SARS-CoV-2. The technology platform has been successful in commercializing blood diagnostics as well as safe and effective vaccines for infectious disease in animal health and has been tested in numerous clinical trials for other indications to date.
COVAXX is currently conducting Phase 1 clinical trials of UB-612 in Taiwan and has an agreement with the University of Nebraska Medical Center to conduct Phase 2 trials in the United States, upon regulatory approval. The company has advanced pre-commitments for over 100 million doses of UB-612 around the globe. In September, COVAXX announced an agreement with Dasa, the largest diagnostic medical company in Brazil to conduct a large-scale human efficacy clinical trial in Brazil.
Lou Reese, co-chief executive officer of COVAXX, said, “The COVAXX vaccine is unique in that it can be stored in the fridge you have at home, moved in the same trucks that deliver groceries and administered anywhere you can get a flu shot.”
Mei Mei Hu, co-chief executive officer of COVAXX, said, “Our team, which now proudly includes Maersk, is committed to addressing the needs of countries where the greatest unmet needs exist today. To do what is in the best interests of society at this time of the global health crisis, we are aligning with the strongest leaders in their respective industries to meet the large-scale demand and compliance requirements that we expect. It is not enough to focus on vaccine development and approvals. We must work in parallel to establish the infrastructure and partners with the strongest capabilities, like Maersk, to safely deliver our vaccine around the world.”